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Background. Studies have implicated abnormalities in epigenetic gene regulation in schizophrenia. Presentation.W eh y p o t h e s i z e
thatidentifyingabnormalitiesinchromatinstructureandtheepigeneticmachineryinperipheralbloodmononuclearcells(PBMC)
fromschizophreniapatientscould(a)helpcharacterizeasubsetofschizophreniapatientsand(b)leadtotargetedpharmacological
interventions. Testing. Investigate the relationship between clinical symptoms, demographics, hormonal ﬂuctuations, substance
abuse, disease characteristics across the major mental illnesses, and epigenetic parameters in PBMC. In addition, examine the
eﬀects of individual antipsychotics, mood stabilizers, as well as experimental agents both as clinically prescribed as well as in
cultured PBMC to understand the eﬀects of these agents on chromatin. Implications. If PBMC could serve as a reliable model
of overall epigenetic mechanisms then this could lead to a “biomarker” approach to revealing pathological chromatin state in
schizophrenia.Thisapproachmayprovideaninformedmethodforselectingchromatinmodifyingagentsforpsychiatricdisorders.
Copyright © 2009 D. P. Gavin and R. P. Sharma. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Background
Chromatin conformation regulates the access and attach-
ment of transcriptional regulators (either activators or
repressors)togenepromoters.Deacetylationofhistones,cat-
alyzedbythehistonedeacetylase(HDAC)familyofenzymes,
dimethylation of lysine 9 of histone 3 (H3K9me2), and DNA
hypermethylation, catalyzed by the DNA methyltransferase
(DNMT) family of enzymes, are several examples of chro-
matin modiﬁcations that lead to a restrictive chromatin state
both site speciﬁcally and globally [1], while hyperacetylation
of histones 3 and 4 promote gene regulation. Because
chromatin “plasticity” can be modiﬁed by conventional
pharmacology, a novel approach to the regulation of gene
expression in clinical populations is possible.
Increasing evidence indicates the existence of epigenetic
gene regulatory abnormalities in schizophrenia. Evidence
supporting this hypothesis includes studies in which mice
administered methionine were found to exhibit some of the
endophenotypesofschizophrenia[2],aswellasstudiesusing
animal and cell models demonstrating that the schizophre-
nia candidate genes the 67kDa isoform of glutamic acid
decarboxylase (GAD67) and reelin are regulated through
epigenetic mechanisms [3–5]. Several postmortem studies
have found an increase in the gene expression of repressive
enzymes including DNMT1 and HDAC1 in schizophrenia
[6–8], while others have demonstrated abnormalities in
the coordination of repressive processes [9]. Finally, studies
using peripheral blood mononuclear cells (PBMC) from
h u m a ns u b j e c t sh a v ef o u n dr e d u c e dl e v e l so ft h e“ o p e n ”
chromatin mark, acetylated histone 3, in schizophrenia
patients compared to nonpsychiatric controls or bipolar
subjects [10, 11], increased levels of the “closed” chromatin
mark H3K9me2 compared to controls [12], and a reduced
ability to alter chromatin structure using HDAC inhibitors
both as clinically administered [13]a sw e l la si nc u l t u r e
[10, 12].
2. Presentationof the Hypothesis
2.1. Understanding Epigenetic Gene Regulatory Abnormalities
in Subsets of Schizophrenia Patients Using PBMC. Unlike
many illnesses in which investigators and clinicians are2 Cardiovascular Psychiatry and Neurology
capable of assessing the diseased tissue while the aﬄicted
patient is still alive, psychiatry is limited by the inaccessibility
of the organ of interest. In addition, representing the higher
order cognitive dysfunctions present in schizophrenia using
animal models is diﬃcult if not impossible. Therefore, there
exists a long history of searching for peripheral markers
capable of reﬂecting the pathology within the brain. There
are several factors which make PBMC particularly useful for
serving as a model of epigenetic gene regulation in the brain.
Firstly, previous studies have demonstrated that PBMC
can provide a reliable means for studying the impact of
environment/life experiences on chromatin structure and
DNA methylation. Fraga et al. [14] examined several epi-
genetic parameters in lymphocytes from monozygotic twins
at ages between 3 and 70 years old. They found that while
3-year-old twins are virtually indistinguishable in terms of
their global levels of DNA methylation, acetylated histone 3,
and acetylated histone 4, 50-year-old twins had signiﬁcant
diﬀerences on these measures. In general, older twins had
greater diﬀerences in terms of epigenetic parameters than
younger twins. In addition, it is important to note that
these diﬀerences were consistent in subjects across at least 12
weeks, indicating that global measures of epigenetic param-
eters in lymphocytes are a reliable method for ascertaining
chromatin state. These ﬁndings indicate that chromatin
from lymphocytes may provide a “molecular ﬁngerprint”
reﬂective of an individual’s environment, life experience,
and stochastic factors which would not be revealed through
genetic testing.
Secondly, the analysis of gene regulation in nucleated
blood cells from living patients undergoing the full evolution
of their disorder, including response to pharmacological,
metabolic and environmental events is the only foreseeable
approach for prospective longitudinal clinical research, and
appears to be a natural progression from single point post-
mortem brain studies. This is because PBMC share much
of the nonsynaptic biochemical environment of neurons,
such as neurohormones, neuropeptides, chemo/cytokines,
metabolites, and medication blood levels. Examples of
epigenetically relevant substances present in the blood
that are found to have relevance to schizophrenia include
methionine, which both worsens psychosis in schizophrenia
and alters chromatin structure in the brain [4, 15, 16],
homocysteine, which has been found to be elevated in
the plasma of schizophrenia patients and is the metabolite
of the DNA methyl donor S-adenosylmethionine [17–20],
and valproic acid (VPA), which we have previously shown
to signiﬁcantly alter global chromatin structure in a dose
dependent manner and aﬀect clinical symptoms [13].
Finally, PBMC contain the full complement of epigenetic
enzymes and machinery found in most tissues including
both neurons and peripheral nucleated cells [21, 22].
Previous studies have shown that PBMC are capable of
reﬂecting overall abnormalities in epigenetic mechanisms
also thought to be present in the brain. For example, in
Huntington disease, a disorder known to be associated with
dysfunctions in histone acetyltransferase, a similar pattern of
transcriptional repression across several chromosomes was
found in blood and brain [23]. Also, several studies have
shown that peripheral markers are able to discern diﬀerences
in chromatin structure in twins discordant for mental illness
[24–26], as well as show similarities in epigenetic parameters
among individuals aﬀected by the same illness [24, 25].
Although, PBMC may be capable of reﬂecting overall
changes in epigenetic mechanisms they would not be appro-
priate for studying brain-speciﬁc processes such as synaptic
plasticity and neurotransmission. Also, the expression of any
onegeneataparticulartimeinaPBMCmaynotbereﬂective
of the expression of the same gene in the brain, just as the
expression of a particular gene in a pyramidal cell at a given
time may not be the same as that in an interneuron or glial
cell. In addition, there are some disorders in which abnormal
epigenetic parameters aretissuespeciﬁc. For example, cancer
cells have particular abnormalities that one would not expect
to ﬁnd in healthy tissue. Therefore, if schizophrenia is
characterized by brain-speciﬁc chromatin alterations then
one would not expect to see changes in PBMC. Also,
global DNA methylation tissue patterns have been found to
signiﬁcantly diﬀer between tissue types [27, 28]. However,
the diﬀerences between individuals or diagnostic groups on
global epigenetic measures have been found to be present
across tissues [23].
We now hypothesize that PBMC may be capable of
reﬂecting the epigenetic machinery within an individual
and provide a means for discerning those subsets of
schizophrenia patients who possess profound abnormalities
in chromatin structureor DNA methylation. It may also help
understand the impact of hormones, medications, and drugs
ofabuseonchromatin.Finally,itcouldprovideatooltoboth
aid in the development of new chromatin altering agents as
well as identify patients most likely to beneﬁt from these
types of medications.
There is now a growing literature to support the idea that
PBMC may be a useful tool for understanding the overall
epigenetic machinery within an individual. In a previous
study we clinically treated schizophrenia and bipolar subjects
for four weeks with the only HDAC inhibitor approved for
psychiatric use,VPA. Similar to animal models in whichVPA
wasshowntoincreaseGAD67mRNAexpressioninthebrain
[2], we found that in subjects with clinically relevant serum
levels of VPA there was a signiﬁcant increase in GAD67
mRNA expression in PBMC [11]. It was our hypothesis
at the time that chromatin in PBMC from schizophrenia
subjectswouldbelessresponsivetoVPA.Thishypothesiswas
conﬁrmedwhenitwasnotedthattherewaslessofanincrease
in the “open” chromatin marks, acetylated histones 3 and
4 in schizophrenia subjects [13]. However, unexpectedly
we also found that at baseline schizophrenia subjects had
signiﬁcantly lower levels of acetylated histone 3 compared
to bipolar subjects [11]. Moreover, we found associations
withthesemeasuresofchromatinstateandsymptomatology.
In these preliminary analyses we found subjects with higher
baseline Young Mania Rating Scale (YMRS) scores to have
higher acetylated histone 3 levels and show greater increases
in acetylated histone 3 after four weeks of clinical treatment.
In addition, subjects with higher baseline acetylated 3 levels
showed greater improvement on the YMRS as well as
the total Positive and Negative Syndrome Scale (PANSS).Cardiovascular Psychiatry and Neurology 3
In other words, those subjects who had the most mania
symptoms were more likely to alter their chromatin in
response to VPA, and those subjects with higher acetylated
histone 3 levels were more likely to respond favorably to VPA
treatment [11].
As a consequence of these studies it was decided to
attempt to perform similar analyses using cultured PBMC.
This model held several advantages relative to clinical
treatment using HDAC inhibitors. Namely, chromatin from
cultured PBMC are protected from unforeseeable or undis-
closed changes in a patient’s physiology such as medication
noncompliance, substance use, environmental exposures
such as infections and diet, hormonal ﬂuctuations, and
diﬀerences in metabolism of HDAC inhibitors. Further,
the in vivo study was limited by the fact that VPA is
the only known chromatin altering drug approved for use
in psychiatric patients, and an in vivo comparison using
chromatin altering medications to nonpsychiatric controls
would not be ethical.
Similar to the previous studies in which systemic admin-
istration of VPA was found to increase GAD67 mRNA
expression in human PBMC and in brains from mice, we
found comparable increases in GAD67 mRNA in human
PBMC cultured with equivalent doses of VPA [11]. Also in
keeping with the in vivo study schizophrenia subjects were
f o u n dt oh a v ea na b n o r m a l l yr e s t r i c t i v ec h r o m a t i ns t a t ea s
indicated by lower levels of acetylated histone 3 and higher
levels of the “closed” chromatin mark, H3K9me2 [10, 12].
Moreover, cultured PBMC were found to be capable of
demonstrating the lack of “plasticity” in schizophrenia chro-
matin structure discovered in the in vivo study, in that we
found less change in GAD67 mRNA expression, H3K9me2
levels, and acetylated histone 3 levels in PBMC cultured with
an HDAC inhibitor compared to nonpsychiatric controls
[10, 12]. Finally, we found that subjects with earlier ages of
onset had higher levels of H3K9me2 [12].
3.Testing the Hypothesis
One means of testing the impact of particular environmental
factors on chromatin would be to culture PBMC with
substances such as hormones, medications, or drugs of
abuse and evaluate the impact of these agents on chromatin
structure. These ﬁndings could then be evaluated in light
of ﬁndings from PBMC taken directly from subjects. For
example, recent epidemiological evidence indicates that
women may be less prone to develop schizophrenia [29],
and data from PBMC cultures reveal sex diﬀerences in the
ability of HDAC inhibitors to alter chromatin structure
[10]. Therefore, it is a reasonable hypothesis that female
sex hormones may have a protective eﬀect in terms of
schizophrenia risk through their ability to alter chromatin.
The impact of sex hormones on chromatin structure could
be tested by culturing PBMC with estrogen, progesterone,
or testosterone. Findings from these experiments could also
be compared to chromatin from animal and postmortem
studies to ascertain whether similar eﬀects are seen in other
tissues.
In addition, extensive studies could be conducted both
in vivo and in vitro using human subjects to examine
whether schizophrenia or characteristics of schizophrenia
are associated with abnormalities in epigenetic machinery
in PBMC. An examination of baseline levels of epigenetic
parameters, such as histone modiﬁcations, DNA methyla-
tion, and epigenetic enzyme expression could be conducted
using samples from human subjects to determine whether
abnormalities exist. Previous studies indicate abnormalities
in the coordination of epigenetic processes in schizophre-
nia [9–11, 13]. Chromatin altering medications could be
administered either directly to human subjects or cultured
with their PBMC as molecular probes into this system.
However, considering VPA is the only chromatin altering
agent clinically approved in psychiatry, this greatly limits
the in vivo approach. If an in vitro culture is capable of
determining thoseschizophrenia patients withabnormalities
in epigenetic gene regulation then information derived from
theculturecouldbeusedtoselectsubjectsmostlikelytoben-
eﬁt from chromatin altering drugs. Once established using in
vitro methods, clinical trials could be implemented whereby
subjects most aﬄicted by abnormal epigenetic mechanisms
could be treated with agents aimed at normalizing these
abnormalities.
4. Implicationsof the Hypothesis
If PBMC, whether exposed to chromatin altering medica-
tions as clinically administered or through in vitro cultur-
ing, could serve as a reliable model of overall epigenetic
mechanisms, then this could lead to a “biomarker” approach
to revealing pathological chromatin state in schizophrenia.
This approach could also provide information regarding the
reaction of a subject’s chromatin to medications prior to
clinical treatment, thereby perhaps providing an informed
method for selecting psychiatric medications for certain dis-
orders. Finally, associating certain epigenetic abnormalities
with symptoms and disease characteristics could lead to a
better understanding of the etiology of symptoms with the
potential for improved diagnostic validity more informed by
a patient’s biology.
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